Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study

International Journal of Cardiology

Volumn 125, Issue 2, 2008, Pages 216-219

  Haugen, Espen ^b   Furukawa, Yutaka ^a,b   Isic, Azra ^a,b   Fu, Michael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Adiponectin; Elderly; Heart failure; NT pro BNP

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELDERLY CARE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 40849123995     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.12.002     Document Type: Article

References (15)

1. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
2. Shibata R., Izumiya Y., Sato K., et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42 (2007) 1065-10674
3. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
4. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
5. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
6. George J., Patal S., Wexler D., et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92 (2006) 1420-1424
7. Tamura T., Furukawa Y., Taniguchi R., et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71 (2007) 623-630
8. Tsutamoto T., Tanaka T., Sakai H., et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28 (2007) 1723-1730
9. McEntegart M.B., Awede B., Petrie M.C., et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28 (2007) 829-835
10. Kintscher U. Does adiponectin resistance exist in chronic heart failure?. Eur Heart J 28 (2007) 1676-1677
11. Bruun J.M., Lihn A.S., Verdich C., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) 527-533
12. Wang B., and Trayhum P. Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pfluger Archiv Eur J Physiol 452 (2006) 418-427
13. Degawa-Yamauchi M., Moss K.A., Bovenkerk J.E., et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 13 (2005) 662-669
14. Carey A.L., Petersen E.W., Bruce C.R., et al. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 49 (2006) 1000-1007
15. Tao L., Gao E., Jiao X., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115 (2007) 1408-1416